GURU.Markets stock price, segment price, and overall market index valuation
The company's share price Evolus Inc.
Evolus competes with AbbVie's Botox in the aesthetic medicine market with its drug Jeuveau. Its stock price tells the story of the battle for market share in this vast market. The chart reflects marketing successes, legal battles, and consumer spending on cosmetic procedures.
Share prices of companies in the market segment - Treatment
Evolus is an aesthetic medicine company whose main product, Jeuveau®, competes with Botox for the correction of expression wrinkles. We classify it in the "Treatment" sector. The chart below shows how the rapidly growing aesthetics market is faring.
Broad Market Index - GURU.Markets
Evolus is an aesthetics company that produces and markets Jeuveau, a direct competitor to Botox. As a significant player, it is included in our GURU.Markets index. The chart below shows the overall market trend. Compare it with Evolus' performance to assess the state of the sector.
Change in the price of a company, segment, and market as a whole per day
EOLS - Daily change in the company's share price Evolus Inc.
The volatility of Evolus, a company in the aesthetic medicine market, reflects competition and consumer trends. Change_co shows the sensitivity to sales of its neurotoxin, which competes with Botox. This metric is key to analyzing the beauty products sector on System.GURU.Markets.
Daily change in the price of a set of shares in a market segment - Treatment
Evolus, Inc. is a company in the aesthetic medicine sector. This chart highlights the sector's high volatility. Comparing it to EOLS, its Botox counterpart, helps assess its competitiveness in this rapidly growing market.
Daily change in the price of a broad market stock, index - GURU.Markets
Evolus is a manufacturer of a neurotoxin (a Botox analog) for aesthetic medicine. The aesthetic medicine market is highly competitive. The chart below shows the average volatility in this sector, allowing you to assess how Evolus shares react to trends.
Dynamics of market capitalization of the company, segment and the market as a whole over 12 months
Annual dynamics of the company's market capitalization Evolus Inc.
For Evolus, Inc., year-over-year performance is a direct competition with Botox. The company's market capitalization growth over the past 12 months reflects its success in promoting its neurotoxin, Jeuveau, in the aesthetic medicine market. Its valuation depends on its ability to capture market share from the leader through marketing and pricing.
Annual dynamics of market capitalization of the market segment - Treatment
Evolus, Inc. is an aesthetic medicine company that directly competes with Botox through its Jeuveau product. Its success depends on its ability to capture share in this vast market. The graph shows how its focused strategy and marketing efforts are driving its superior growth.
Annual dynamics of market capitalization of broad market stocks, index - GURU.Markets
Evolus, with its Botox analogue, is betting on the "beauty economy." Its business is cyclical and dependent on consumer discretionary spending on cosmetic procedures. The company's stock price reflects both overall economic trends and its ability to compete with the giant Allergan.
Dynamics of market capitalization of the company, segment and the market as a whole for the month
Monthly dynamics of the company's market capitalization Evolus Inc.
The value of Evolus, a manufacturer of cosmetic injectables, depends on consumer spending. The monthly fluctuations in the chart reflect sales data for its Jeuveau product, which competes with Botox, and its ability to gain share in the rapidly growing aesthetic medicine market.
Monthly dynamics of market capitalization of the market segment - Treatment
Evolus is a company operating in the aesthetic medicine market. Its flagship product, Jeuveau, is a direct competitor to Botox for the correction of expression wrinkles. The graph below illustrates the dynamics of the rapidly growing aesthetic medicine sector, where branding and marketing play a key role in the competition.
Monthly dynamics of market capitalization of broad market stocks, index - GURU.Markets
Evolus is a company specializing in aesthetic medicine, whose main product is a Botox analogue. Demand for these procedures depends on consumer discretionary spending, making the business sensitive to economic cycles. The chart below shows how the company's shares react to changes in consumer confidence.
Dynamics of market capitalization of the company, segment and the market as a whole for the week
Weekly dynamics of the company's market capitalization Evolus Inc.
Evolus produces Jeuveau, a Botox competitor. Its weekly stock price reflects its ability to gain market share in aesthetic medicine, its marketing efforts, and the outcome of patent disputes. The chart tells the story of the battle in the beauty injection market.
Weekly dynamics of market capitalization of the market segment - Treatment
Evolus, like other companies in the aesthetic medicine sector, is dependent on overall consumer spending on cosmetic procedures. Weekly stock price fluctuations in this segment reflect the overall demand dynamics. The chart below shows how the company aligns with the pulse of the beauty industry.
Weekly dynamics of market capitalization of stocks of the broad market, index - GURU.Markets
Evolus, Inc. produces aesthetic products and competes with Botox. Demand for "beauty injections" depends on discretionary spending. The chart shows how strongly the company's shares respond to overall economic sentiment, serving as an indicator of consumer confidence.
Market capitalization of the company, segment and market as a whole
EOLS - Market capitalization of the company Evolus Inc.
The Evolus, Inc. chart tells the story of competition in the aesthetic medicine market. Its market capitalization reflects the market's valuation of Jeuveau, a direct competitor to Botox. The dynamics reveal the battle for market share, marketing efforts, and investor confidence in the growing demand for cosmetic procedures.
EOLS - Share of the company's market capitalization Evolus Inc. within the market segment - Treatment
Evolus, Inc. competes directly with Botox, capturing a growing share of the aesthetic medicine market with its drug Jeuveau. Its market capitalization reflects its success in challenging Allergan's dominance and its exclusive focus on the aesthetic market.
Market capitalization of the market segment - Treatment
Evolus has challenged Botox with its product, Jeuveau. How big is the entire beauty industry? The graph below shows the overall market capitalization of this sector. Its dynamics reflect the global desire for youth and beauty, creating a multi-billion dollar market for such products.
Market capitalization of all companies included in a broad market index - GURU.Markets
The Evolus chart is a visualization of the competitive landscape in the aesthetic medicine market. The market capitalization of the company, which produces a Botox analogue (Jeuveau), is directly dependent on its ability to capture market share from giant AbbVie. This diagram illustrates how a single product can determine the fate of an entire company.
Book value capitalization of the company, segment and market as a whole
EOLS - Book value capitalization of the company Evolus Inc.
Evolus's assets are its inventory of aesthetic medicine products (Botox analogs), as well as its IT platform and commercial infrastructure. Its book value reflects the value of these assets, which form the foundation of its business. The chart below shows how the value of this material foundation has changed.
EOLS - Share of the company's book capitalization Evolus Inc. within the market segment - Treatment
Evolus, Inc. operates in the aesthetic medicine industry, and although its business is focused on a single product, it requires physical support. These include distribution centers with special storage conditions and offices to manage global supply chains. The chart shows how this niche company's physical assets compare to those of pharmaceutical giants.
Market segment balance sheet capitalization - Treatment
Evolus is an aesthetic medicine company. Compared to the capital-intensive pharmaceutical industry, its asset-light model is comparable to the industry's. The industry's asset chart reflects the value of its factories. Evolus doesn't own them. Its capital is its brand and product license.
Book value of all companies included in the broad market index - GURU.Markets
Evolus' assets include not only the Jeuveau neurotoxin brand, but also R&D centers and a distribution network. The graph below indirectly illustrates the scale of its operations, which requires financial support to compete in the aesthetic medicine market.
The ratio of market capitalization to book capitalization of a company, segment, and the market as a whole
Market capitalization to book capitalization ratio - Evolus Inc.
Evolus sells a Botox analogue. Its value lies in its brand and marketing, not its production assets. The chart below shows how the market assessed its ability to compete with the giant Allergan in the aesthetic medicine market.
Market to book capitalization ratio in a market segment - Treatment
Evolus produces Jeuveau, a Botox competitor. Its value is determined by the success of this product and its ability to compete with the market leader. The chart shows how the market evaluates its market prospects relative to its tangible and intangible assets.
Market to book capitalization ratio for the market as a whole
Evolus is a company that produces the aesthetic product Jeuveau, a direct competitor to Botox. Its valuation, unlike the average in this chart, is based on its ability to capture share in the vast and growing aesthetic medicine market. The market views it as a growth story, with brand and marketing more important than the value of its production assets.
Debts of the company, segment and market as a whole
EOLS - Company debts Evolus Inc.
Evolus competes in the aesthetic medicine market with its neurotoxin, a Botox analogue. This chart shows how the company is funding its commercial expansion. The company is raising debt and equity capital to support aggressive marketing and gain market share from a much larger competitor, which requires significant financial infusions.
Market segment debts - Treatment
Evolus is a company specializing in aesthetic medicine, whose main product is the neurotoxin Jeuveau, a Botox competitor. The company is in a phase of aggressive growth, investing in marketing to capture market share. This chart shows how its debt policy reflects this strategy and how it finances its competition with beauty industry giants.
Market debt in general
Debt to book value of the company, segment and market as a whole
The company's debt to book capitalization ratio Evolus Inc.
Evolus is a company operating in the aesthetic medicine market, whose main product is a Botox analogue. In this industry, enormous resources are spent on marketing and competition. This chart shows how the company uses debt capital to gain market share. It is an indicator of its financial strategy and aggressiveness in competing with industry giants.
Market segment debt to market segment book capitalization - Treatment
Evolus is a company operating in the aesthetic medicine sector, known for its drug Jeuveau, a Botox competitor. This chart shows the debt burden in the biotech sector. It helps us understand how companies in this competitive niche finance their marketing and clinical research to capture market share in the lucrative market.
Debt to book value of all companies in the market
Evolus is a company operating in the aesthetic medicine sector, best known for its drug that competes with Botox. Market entry and competition require significant marketing expenditures. This graph of total market debt allows us to assess how the company finances its battle for market share—through shareholders or through borrowing.
P/E of the company, segment and market as a whole
P/E - Evolus Inc.
Evolus is a company specializing in aesthetic medicine, and its main product, Jeuveau®, is a direct competitor to Botox®. This chart shows how investors view the pure play in the neurotoxin market. The dynamics depend on the company's ability to capture market share from giant AbbVie (owner of Botox) and expand its presence.
P/E of the market segment - Treatment
Evolus is a company specializing in aesthetic medicine. Its flagship product, Jeuveau, is a direct competitor to Botox and is used to correct expression wrinkles. The company has challenged the market leader. This chart shows the average valuation for the medical services sector, reflecting how investors view the growing aesthetic procedures market.
P/E of the market as a whole
Evolus is a company operating in the aesthetic medicine sector. Its main product is the neurotoxin Jeuveau, a direct competitor to Botox. The company's valuation depends on its ability to capture market share from the giant AbbVie. This overall sentiment chart is important because aesthetic procedures are discretionary expenses, but for Evolus, competitive pressure is more important.
Future P/E of the company, segment and market as a whole
Future (projected) P/E of the company Evolus Inc.
Evolus, Inc. is a company specializing in aesthetic medicine. Its flagship product, Jeuveau, is a direct competitor to Botox. This chart reflects expectations for its ability to compete in the neurotoxin market. The company's valuation depends on its market share and successful expansion of its product line in the aesthetics sector.
%20P%2FE%20Evolus%20Inc.&width=1500&height=450&colorIndex=35&filename=GURU_Markets_-_Chart-of-the-companys-future-projected-PE-Evolus-Inc.&v=1772629434804 "Chart of the company's future (projected) P/E Evolus Inc.")
Future (projected) P/E of the market segment - Treatment
Evolus is a company operating in the aesthetic medicine market, its main product being the neurotoxin Jeuveau, a direct competitor to Botox. This chart reflects investors' views on its ability to compete with the giant Allergan. Comparing its profit forecasts to the sector reveals investors' confidence in its marketing strategy and market share growth potential.
%20P%2FE%20graph%20of%20the%20market%20segment%20-%20Treatment&width=1500&height=450&colorIndex=36&filename=GURU_Markets_-_Future-projected-PE-graph-of-the-market-segment-Treatment&v=1772629434821 "Future (projected) P/E graph of the market segment - Treatment")
Future (projected) P/E of the market as a whole
Evolus is a company operating in the aesthetic medicine market, primarily known for its neurotoxin, a Botox competitor. Demand for aesthetic procedures is sensitive to the state of the economy and disposable income. This chart, reflecting consumer confidence, helps assess how much people are willing to spend on beauty enhancement procedures.
%20P%2FE%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=37&filename=GURU_Markets_-_Chart-of-the-future-projected-PE-of-the-market-as-a-whole&v=1772629434925 "Chart of the future (projected) P/E of the market as a whole")
Profit of the company, segment and market as a whole
Company profit Evolus Inc.
Evolus, Inc. is a company operating in the aesthetic medicine industry, whose main product is Jeuveau, a neurotoxin that competes with Botox. The company's profitability depends on its ability to capture market share in this highly competitive market. This chart shows its financial performance as it struggles to gain recognition among doctors and patients.
Profit of companies in the market segment - Treatment
Evolus specializes in aesthetic medicine, its main product being the neurotoxin Jeuveau, a direct competitor to Botox. The company operates in the fast-growing but highly competitive market of "beauty injections." The profitability chart for the medical cosmetology sector demonstrates the size of this market and how both giants and ambitious new players like Evolus coexist within it.
Overall market profit
Evolus is a company operating in the aesthetic medicine sector, known for its Jeuveau, a competitor to Botox. The company's growth depends on consumer spending on cosmetic procedures, which, in turn, is an indicator of discretionary spending and consumer confidence. This demonstrates how the beauty and wellness sector contributes to the economy.
Future (predicted) profit of the company, segment and market as a whole
Future (projected) profit of the company Evolus Inc.
Evolus produces Jeuveau, an injectable product that directly competes with Botox. This chart shows expectations for its ability to capture market share in aesthetic medicine. Profitability depends on successful marketing and price competition with the market leader.
%20profit%20of%20the%20company%20Evolus%20Inc.&width=1500&height=450&colorIndex=41&filename=GURU_Markets_-_Graph-of-future-projected-profit-of-the-company-Evolus-Inc.&v=1772629434980 "Graph of future (projected) profit of the company Evolus Inc.")
Future (predicted) profit of companies in the market segment - Treatment
Evolus, Inc. is a company specializing in aesthetic medicine, whose main product is the neurotoxin Jeuveau, a Botox competitor. The data in the graph shows profit projections for the aesthetic medicine sector. This allows us to assess how successfully the company is competing in a rapidly growing market and how this compares to overall trends.
%20profits%20of%20companies%20in%20a%20market%20segment%20-%20Treatment&width=1500&height=450&colorIndex=42&filename=GURU_Markets_-_Graph-of-future-predicted-profits-of-companies-in-a-market-segment-Treatment&v=1772629435031 "Graph of future (predicted) profits of companies in a market segment - Treatment")
Future (predicted) profit of the market as a whole
This chart illustrates expectations for a company operating in the aesthetic medicine market. Evolus's profit forecast hinges on sales of its neurotoxin, Jeuveau, a direct competitor to Botox. The company's ability to grow its share in this highly competitive market and successful marketing are key to revenue growth.
%20profits%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=43&filename=GURU_Markets_-_Chart-of-future-predicted-profits-of-the-market-as-a-whole&v=1772629435087 "Chart of future (predicted) profits of the market as a whole")
P/S of the company, segment and market as a whole
P/S - Evolus Inc.
Evolus competes in the aesthetic medicine market with its neurotoxin, a Botox analogue. This chart shows how investors assess its ability to capture market share from established leaders. The multiple reflects revenue growth expectations and confidence in the company's marketing strategy.
P/S market segment - Treatment
Evolus markets the neurotoxin Jeuveau, a direct competitor to Botox, in the aesthetic medicine market. The company's revenue is entirely dependent on the success of this product and its market penetration. This chart shows the average valuation in the biotech and aesthetics sectors, helping to understand how investors assess Evolus's ability to compete with the giants and grow revenue.
P/S of the market as a whole
Evolus is a company operating in the aesthetic medicine market, whose main product is a Botox analogue. Its revenue depends on successfully competing with the market leader and expanding its customer base. This graph, which displays the average revenue estimate for Evolus, helps understand how the market views its growth prospects in the highly competitive beauty industry.
Future P/S of the company, segment and market as a whole
Future (projected) P/S of the company Evolus Inc.
Evolus is a company specializing in aesthetic medicine, and its main product, Jeuveau, is a competitor to Botox. The company's future revenue depends on its ability to capture market share from the market leader and expand its presence. This chart shows how investors assess the company's growth prospects in the highly competitive aesthetic injection market.
%20P%2FS%20Evolus%20Inc.&width=1500&height=450&colorIndex=47&filename=GURU_Markets_-_The-graph-of-the-companys-future-projected-PS-Evolus-Inc.&v=1772629435336 "The graph of the company's future (projected) P/S Evolus Inc.")
Future (projected) P/S of the market segment - Treatment
Evolus is a company specializing in aesthetic medicine, and its main product, Jeuveau, is a competitor to Botox. This chart compares the company's estimated future sales with other companies in the skincare industry. It shows how investors assess its ability to capture share in the highly competitive neurotoxin market and expand its product portfolio.
%20P%2FS%20market%20segment%20graph%20-%20Treatment&width=1500&height=450&colorIndex=48&filename=GURU_Markets_-_Future-projected-PS-market-segment-graph-Treatment&v=1772629435357 "Future (projected) P/S market segment graph - Treatment")
Future (projected) P/S of the market as a whole
Evolus is a company specializing in aesthetic medicine, whose main product is a Botox analogue. Its growth depends on consumer spending on cosmetic procedures. Evolus's success in competing with the market leader is an indicator of the state of this growing segment, which is part of the overall picture of consumer spending on beauty and health.
%20P%2FS%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=49&filename=GURU_Markets_-_Chart-of-the-future-projected-PS-of-the-market-as-a-whole&v=1772629435415 "Chart of the future (projected) P/S of the market as a whole")
Sales of the company, segment and market as a whole
Company sales Evolus Inc.
Evolus, Inc. specializes in aesthetic medicine, and its main product is the neurotoxin Jeuveau, a direct competitor to Botox. This chart shows Jeuveau sales to cosmetologists and clinics, reflecting the company's share of the rapidly growing aesthetic treatment market and its ability to compete with the industry leader.
Sales of companies in the market segment - Treatment
Evolus, Inc. is a company specializing in aesthetic medicine, with its flagship product, Jeuveau®, a direct competitor to Botox. The company is focused exclusively on the rapidly growing market for aesthetic neurotoxins. This chart shows overall sales in the sector, illustrating the high demand for cosmetic procedures and the intense competition in this lucrative market.
Overall market sales
Evolus is a company specializing in aesthetic medicine, its main product being the neurotoxin Jeuveau, a Botox competitor. This graph, reflecting consumer spending on beauty and personal care, is a direct driver for Evolus. Rising disposable incomes allow more people to spend money on non-essential cosmetic procedures.
Future sales volume of the company, segment and market as a whole
Future (projected) sales of the company Evolus Inc.
Evolus is a company specializing in aesthetic medicine, its main product being the neurotoxin Jeuveau, a direct competitor to Botox. The company's future revenue depends on its ability to capture a share of the growing aesthetic procedures market. This chart shows analysts' forecasts for demand for cosmetic injectables and Evolus's success in the competitive landscape.
%20sales%20of%20the%20company%20Evolus%20Inc.&width=1500&height=450&colorIndex=53&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-the-company-Evolus-Inc.&v=1772629435833 "Schedule of future (projected) sales of the company Evolus Inc.")
Future (projected) sales of companies in the market segment - Treatment
Evolus, Inc. is a company specializing in aesthetic medicine, its main product being the neurotoxin Jeuveau, a Botox competitor. This chart shows projected revenue for the entire aesthetic medicine sector. It reflects expectations for growth in consumer spending on cosmetic procedures, a key market for Evolus.
%20sales%20of%20companies%20in%20the%20market%20segment%20-%20Treatment&width=1500&height=450&colorIndex=54&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-companies-in-the-market-segment-Treatment&v=1772629435891 "Schedule of future (projected) sales of companies in the market segment - Treatment")
Future (projected) sales of the market as a whole
Evolus is a company specializing in aesthetic medicine, whose main product is a Botox analogue. Demand for its products is purely discretionary and heavily dependent on consumer disposable income. This graph, reflecting consumer confidence, is key for Evolus. During periods of economic growth, people are more willing to spend money on cosmetic procedures to improve their appearance.
%20sales%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=55&filename=GURU_Markets_-_Schedule-of-future-predicted-sales-of-the-market-as-a-whole&v=1772629435952 "Schedule of future (predicted) sales of the market as a whole")
Marginality of the company, segment and market as a whole
Company marginality Evolus Inc.
Evolus is a company specializing in aesthetic medicine, whose main product is a Botox analogue. This chart shows profitability in the highly competitive beauty industry. Evolus's effectiveness depends on marketing spend on promoting its product to doctors and patients, as well as on price competition with the market leader.
Market segment marginality - Treatment
Evolus offers the cosmetic neurotoxin Jeuveau, a direct competitor to Botox. The company's entire strategy is built on capturing share in this lucrative market. This chart shows how successfully Evolus is commercializing its product compared to other pharmaceutical and biotech companies, reflecting the effectiveness of its marketing strategy.
Market marginality as a whole
Evolus is an aesthetics company whose main product is a competitor to Botox. The company's profitability depends on its ability to gain market share in the highly competitive aesthetics market. This total market profitability chart contextualizes a sector driven by consumer spending on beauty, where branding and marketing are crucial to success.
Employees in the company, segment and market as a whole
Number of employees in the company Evolus Inc.
Evolus is a company operating in the aesthetic medicine market, whose main product is Jeuveau, a Botox competitor. This chart shows the growth of its sales team. The increase in staff, primarily sales representatives, directly reflects the company's efforts to capture share in the highly competitive market for injectable neurotoxins.
Share of the company's employees Evolus Inc. within the market segment - Treatment
This figure reflects Evolus, Inc.'s niche in the aesthetic medicine market. The company's share of the sector is focused on selling Jeuveau, a botulinum toxin-based injectable that directly competes with Botox. This team of marketers and salespeople is striving to gain market share in the highly competitive but rapidly growing "beauty injection" market.
Number of employees in the market segment - Treatment
Evolus, Inc. is a company operating in the aesthetic medicine industry. Its main product is the neurotoxin Jeuveau, a direct competitor to Botox. This market requires significant investment in marketing and outreach to estheticians. This graph illustrates the rapid growth of the beauty industry, which is creating thousands of jobs for medical professionals and marketers.
Number of employees in the market as a whole
Evolus, Inc. specializes in aesthetic medicine, specifically a Botox alternative. Demand for its products is discretionary. This overall occupancy rate reflects consumer financial confidence, which allows them to spend money on cosmetic procedures to enhance their appearance.
Market capitalization per employee (in thousands of dollars) of the company, segment, and market as a whole
Market capitalization per employee (in thousands of dollars) of the company Evolus Inc. (EOLS)
Evolus is a company operating in the aesthetic medicine market, with its main product being a Botox analogue. This chart shows how the market values its niche business. Its high market capitalization per employee indicates the company's focus on marketing and sales of a single key product, allowing it to be effective with a relatively small team.
%20of%20the%20company%20Evolus%20Inc.%20(EOLS)&width=1500&height=450&colorIndex=63&filename=GURU_Markets_-_Chart-of-market-capitalization-per-employee-in-thousands-of-dollars-of-the-company-Evolus-Inc.-EOLS&v=1772629436465 "Chart of market capitalization per employee (in thousands of dollars) of the company Evolus Inc. (EOLS)")
Market capitalization per employee (in thousands of dollars) in the market segment - Treatment
Evolus specializes in the aesthetic medicine market and competes with Botox. This indicator reflects the effectiveness of its commercial strategy and brand strength. A high value relative to the industry may indicate successful market share capture and high product margins, driven by a focused team.
%20by%20market%20segment%20-%20Treatment&width=1500&height=450&colorIndex=64&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-by-market-segment-Treatment&v=1772629436476 "Market capitalization per employee (in thousands of dollars) by market segment - Treatment")
Market capitalization per employee (in thousands of dollars) for the overall market
Evolus, Inc. is a company operating in the aesthetic medicine market, whose main product is a Botox competitor. This chart shows how the market assesses its ability to compete with the giants. The company's per-employee valuation will depend on the success of its marketing strategy and its ability to capture share in the high-margin market.
%20for%20the%20overall%20market&width=1500&height=450&colorIndex=65&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-for-the-overall-market&v=1772629436525 "Market capitalization per employee (in thousands of dollars) for the overall market")
Profit per employee (in thousands of dollars) for the company, segment, and market as a whole
Profit per employee (in thousands of dollars) of the company Evolus Inc. (EOLS)
Evolus (EOLS) is an aesthetic medicine company. Their only product is Jeuveau, a direct competitor to Botox (a neurotoxin). This chart shows the efficiency of a "single-product business." The company's entire profit per employee (primarily in R&D and marketing) depends on how successfully they "nibble" market share from the giant AbbVie (the owner of Botox).
%20Chart%20Evolus%20Inc.%20(EOLS)&width=1500&height=450&colorIndex=66&filename=GURU_Markets_-_Company-Profit-Per-Employee-in-thousands-of-dollars-Chart-Evolus-Inc.-EOLS&v=1772629436581 "Company Profit Per Employee (in thousands of dollars) Chart Evolus Inc. (EOLS)")
Profit per employee (in thousands of dollars) in the market segment - Treatment
Evolus is a company specializing in aesthetic medicine, its flagship product being Jeuveau, a Botox competitor. It's a business heavily dependent on marketing and sales to estheticians. This chart shows how effectively Evolus monetizes its product. It serves as a benchmark for assessing how successfully the company is capturing market share from giants using its sales and marketing staff.
%20in%20the%20market%20segment%20-%20Treatment&width=1500&height=450&colorIndex=67&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-in-the-market-segment-Treatment&v=1772629436623 "Chart of profit per employee (in thousands of dollars) in the market segment - Treatment")
Profit per employee (in thousands of dollars) for the market as a whole
Evolus (EOLS) is a company operating in the aesthetic medicine industry. Their main product is Jeuveau, a direct competitor to Botox. It's a marketing and R&D business. This graph shows their struggle for market share. They need to spend huge amounts of money on marketing (to convince doctors and patients), which eats into their profits. An increase in this figure would indicate that their product has taken off and is covering their personnel costs.
%20for%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=68&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-for-the-market-as-a-whole&v=1772629436727 "Chart of profit per employee (in thousands of dollars) for the market as a whole")
Sales to employees of the company, segment and market as a whole
Sales per company employee Evolus Inc. (EOLS)
Evolus is a company operating in the aesthetic medicine market, whose main product is a Botox analogue. This chart shows how the company competes with industry giants. The growth in revenue per employee reflects the success of its marketing strategy and its expanding share of the lucrative aesthetic procedures market.
&width=1500&height=450&colorIndex=69&filename=GURU_Markets_-_Sales-chart-per-company-employee-Evolus-Inc.-EOLS&v=1772629436791 "Sales chart per company employee Evolus Inc. (EOLS)")
Sales per employee in the market segment - Treatment
Evolus is a company specializing in aesthetic medicine, and their main product is Jeuveau, a Botox competitor. This graph shows the average revenue per employee in this segment. It demonstrates how productive their sales team is in promoting their product in the highly competitive aesthetics market.
Sales per employee for the market as a whole
Evolus is a company specializing in aesthetic medicine. Their only product is Jeuveau (known as Nabota in Korea), a direct competitor to Botox. It's a niche biopharmaceutical company. This chart shows how well their team (primarily marketing and sales) competes with the giant AbbVie (the owner of Botox).
Short shares by company, segment and market as a whole
Shares shorted by company Evolus Inc. (EOLS)
Evolus, the manufacturer of Jeuveau, is a direct competitor to Botox (a neurotoxin). The bearish sentiment seen in this chart is due to the fierce competition. Bears are betting that Evolus will be unable to capture significant market share from giant AbbVie (owner of Botox) and other players, which will require massive marketing expenditures.
&width=1500&height=450&colorIndex=72&filename=GURU_Markets_-_Short-Shares-Chart-for-the-Company-Evolus-Inc.-EOLS&v=1772629437015 "Short Shares Chart for the Company Evolus Inc. (EOLS)")
Shares shorted by market segment - Treatment
Evolus is a company specializing in "aesthetic" medicine. Its flagship product (Jeuveau) directly competes with Botox for wrinkle reduction. This chart reflects the overall sentiment in the sector. It reflects investor concerns that consumers will cut back on "beauty procedures" during the recession, which will hurt all players in this niche.
Shares shorted by the overall market
Evolus (EOLS) is the maker of Geuvo, a direct competitor to Botox. It's 100% in the aesthetics sector. When this market pessimism indicator rises, investors anticipate a recession. They understand that during a crisis, consumers will first forego expensive cosmetic procedures, postponing visits to the esthetician, which directly impacts EOLS.
RSI 14 indicator for a company, segment, and market as a whole
The company's RSI 14 indicator Evolus Inc. (EOLS)
Evolus (EOLS) is a company in the aesthetic medicine sector. Their key product, Jeuveau (also known as Nuceiva), is a direct competitor to Botox. Their business is a "war" for market share in the cosmetology industry. This chart measures hype. It shows "overheated" (above 70) due to strong sales growth data or "oversold" (below 30) due to fears of a price war.
&width=1500&height=450&colorIndex=75&filename=GURU_Markets_-_RSI-14-indicator-chart-for-the-companys-stock-Evolus-Inc.-EOLS&v=1772629437103 "RSI 14 indicator chart for the company's stock Evolus Inc. (EOLS)")
RSI 14 Market Segment - Treatment
Evolus (EOLS) is a company in the aesthetics industry. Their flagship product, Jeuveau, is a direct competitor to Botox (a neurotoxin). This chart tracks the overall sentiment in the Medical/Aesthetic Services sector. It helps us understand whether Evolus's performance reflects their "Botox wars" or whether the entire industry is overheated or oversold.
RSI 14 for the overall market
Evolus (EOLS), the manufacturer of Botox, sees consumer confidence in this chart. "Beauty injections" are pure luxury. In moments of euphoria and the "wealth effect," people are eager to spend on aesthetics. In times of panic and recession, these "non-essential" expenses are among the first to be curtailed.
Analyst consensus forecast for the company's share price, the segment, and the market as a whole
Analyst consensus stock price forecast EOLS (Evolus Inc.)
Evolus (EOLS) is an aesthetic medicine company whose sole product, Jeuveau (known as Nabota in Korea), is a direct competitor to Botox for wrinkle correction. This chart shows the average 12-month Wall Street forecast. It reflects analysts' expectations for Jeuveau's ability to capture market share from giant AbbVie (Botox).
&width=1500&height=450&colorIndex=78&filename=GURU_Markets_-_A-chart-showing-analyst-consensus-forecasts-for-the-expected-stock-price.-EOLS-Evolus-Inc.&v=1772629437165 "A chart showing analyst consensus forecasts for the expected stock price. EOLS (Evolus Inc.)")
The difference between the consensus estimate and the actual stock price EOLS (Evolus Inc.)
Evolus (EOLS) is an aesthetics company whose flagship product, Jeuveau, is a direct competitor to Botox. This chart shows their market share battle. It measures the gap between the price and the consensus target, reflecting analysts' perceived potential to gain market share from giant AbbVie in the Botox wars.
&width=1500&height=450&colorIndex=79&filename=GURU_Markets_-_A-chart-showing-the-difference-between-the-consensus-forecast-and-the-actual-stock-price.-EOLS-Evolus-Inc.&v=1772629437225 "A chart showing the difference between the consensus forecast and the actual stock price. EOLS (Evolus Inc.)")
Analyst consensus forecast for stock prices by market segment - Treatment
Evolus is a pure bet on aesthetics. The company challenged Allergan (AbbVie) with the launch of Jeuveau (Newtox), a direct competitor to Botox for wrinkle smoothing. This chart shows analysts' overall expectations for the entire therapeutic (aesthetic) pharmaceutical sector. It reflects whether experts believe the "beauty injection" market will grow or decline.
Analysts' consensus forecast for the overall market share price
Evolus is a company specializing in aesthetic medicine. Their main product (Jeuveau) is a direct competitor to Botox, a neurotoxin used to smooth out wrinkles. This chart shows overall market sentiment. For Evolus, whose business is discretionary beauty spending, the overall optimism of analysts is a key indicator. It signals consumers' willingness to spend on cosmetic procedures.
AKIMA index of the company, segment and market as a whole
AKiMA Company Index Evolus Inc.
Evolus (EOLS) is a single-product company. Their business is Jeuveau, a competitor to Botox (a neurotoxin) for aesthetic (cosmetic) use. This chart is an indicator of their battle. It measures their ability to win market share (doctors and patients) from giant AbbVie (Botox) in the highly competitive but growing market for beauty injections.
AKIMA Market Segment Index - Treatment
Evolus (EOLS) is a single-product aesthetic biotech; the company is a pure-play competitor to Botox, selling its own neurotoxin (Jeuveau) for wrinkle smoothing. This summary metric evaluates R&D. The graph shows the segment average. This is a benchmark: how does this ultra-niche (Botox competitor) model (EOLS) differentiate itself from the average pharma company?
The AKIM Index for the overall market
Evolus is an aesthetics company that has challenged Botox with its Jeuveau product. It focuses on millennials. This chart, reflecting the market average, is the backdrop. It helps assess how this growth story in the beauty industry, driven by discretionary spending on beauty, compares to overall macroeconomic trends.
